Showing 1521-1530 of 3044 results for "".
- Hair Loss Drug May Boost Heart Healthhttps://practicaldermatology.com/news/hair-loss-drug-may-boost-heart-health/2457833/Oral minoxidil may improve blood flow to the brain, lower blood pressure and increase elasticity in the blood vessels, according to a new study in mice. The article is published in the American Journal of Physiology&mdash
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- CareCredit Moves Into Day and Med Spa Marketshttps://practicaldermatology.com/news/carecredit-moves-into-day-and-med-spa-markets/2457847/CareCredit is expanding into the day and medical spa markets. As part of this new program, CareCredit partnered with both the American Med Spa Association and the Spa Industry Association to bring the benefits of CareCredit to their practices. Providers can now offer clients acces
- Mandy Moore, Garnier Team Up for Beauty Product Recyclinghttps://practicaldermatology.com/news/mandy-moore-garnier-team-up-for-beauty-product-recycling/2457854/Nearly half of Americans don’t recycle their beauty and personal care products, which is why they account for a significant amount of landfill waste, and This Is Us star Mandy Moore, #GarnierGirl and brand ambassador, is teaming up with Garnier and DoSomething.org to kick off the seco
- Skin Microbiome May Protect Against Skin Cancerhttps://practicaldermatology.com/news/skin-microbiome-may-protect-against-skin-cancer/2457857/Beneficial skin bacteria may protect against skin cancer, according to a new study in Science Advances. “We have identified a strain of Staphylococcus epidermidis, common on healthy human skin, that exerts a selective ability to inhibit the growth of some cancers,” sa
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (